Skip to main content
OpenTrials
Completed

NCT Number: NCT01193634

Clinical Evaluation Of The PARADYM RF Device

The PARADYM RF ICDs (DR, VR and CRT)have been implemented with 3 innovative features:

The new RV autothreshold algorithm which will help the physician in his diagnosis avoiding potential lost of capture.

Then, the ICD devices have also the capability to be remotely interrogated through the remote monitoring system whose performances will be reported during the study.

Finally the study will report the electrical and handling performances of the new left ventricular lead.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Sack

München, 80804, Germany

About this study

In the PARADYM RF clinical study, the sponsor aims at:

  • Demonstrating the performances of the right ventricular autothreshold algorithm ;
  • Reporting the adverse events documented in the study;
  • Reporting electrical performances of Sorin Group PARADYM ICDs, in order to validate that the performances of those devices are in conformance with longevity and effectiveness objectives;
  • Assessing the user satisfaction (patient and physician) of the remote monitoring solution and the overall availability of the system in terms of data.
  • Reporting the Situs 2 MV left ventricular lead performances;
  • Reporting the Situs 2 MV LV lead mechanical handling.

Thus, this study intends to show that PARADYM RF ICDs operate safely and appropriately in intended-use as part of an ICD system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • In case of implantation of VR 9250: patient has been prescribed the implantation or replacement of a single-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC2 guidelines or any relevant currently-approved local guidelines for the implantation or replacement of single-chamber ICD;
  • In case of implantation of DR 9550: patient has been prescribed the implantation or replacement of a dual-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC2 guidelines or any relevant currently-approved local guidelines for the implantation or replacement of dual-chamber ICD;
  • In case of implantation of CRT 9750: patient has been prescribed the implantation or replacement of a triple-chamber ICD system accordingly to the relevant currently-approved ACC/AHA/ESC3 guidelines or any relevant currently-approved local guidelines for the implantation or replacement of triple-chamber ICD;

Exclusion criteria

  • 1 VT/VF is associated with drug toxicity, electrolyte imbalance, hypoxia, or other reversible cause;
  • 2 VT/VF occurred during the acute phase of infarction (< 3 weeks) or during an unstable ischemic phase;
  • 3 VF was caused by electrocution;
  • 4 Incessant VT/VF ;
  • 5 Implanted pacemaker that is not going to be explanted or otherwise disabled;
  • 6 Patient is unable to attend the scheduled follow-ups at the implanting centre;
  • 7 Patient is already enrolled in another ongoing clinical study;
  • 8 Patient is unable to understand the aim of the study and its procedure;
  • 9 Patient refuses to cooperate;
  • 10 Patient is unable or refuses to provide informed consent;
  • 11 Patient is minor (less than 18-year old);
  • 12 Patient is pregnant;
  • 13 Patient has life expectancy of less than 1 year;
  • 14 Patient is forfeiture of freedom or under guardianship.

Treatment and study plan

VR 9250 / DR 9550 / CRT 9750

Device

Active implantable defibrillators range

Other names: 9250 / 9550 / 9750

Primary outcomes

  1. Demonstration of the Right ventricular (RV) autothreshold algorithm performances

    Time frame: 1 month

    Demonstrate that the automatic RV pacing thresholds measures are equivalent to the manual test.

Secondary outcomes

  1. Incidence of adverse events

    Time frame: 12 months

    Any adverse event will be documented throughout the study and will be reported.

  2. ICD electrical performances

    Time frame: 12 months

    Report all ICD electrical performances of the Paradym RF ICD.

  3. Evaluation of the left ventricular lead performances

    Time frame: 12 months

    Report the electrical performances and lead mechanical handling at implant.

  4. Evlauation of the Remote Monitoring Solution

    Time frame: 12 months

    Ensure the Home Monitoring setup procedure and daily life use are user friendly for the patient and the back office is convenient for the physician.

Sponsors and collaborators

Lead sponsor

LivaNova

Industry

Registry information

Official study title

Clinical Evaluation Of The PARADYM RF Device SORIN GROUP'S New IDC Platform

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Sep 2, 2010
Registry last updated
Jun 18, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.